/Companies

DexCom

NASDAQ: DXCM

San Diego, US · Delaware corporation · 9,000 employees on LinkedIn · 2 known investors

Find your way into DexCom

Sign up to see every warm intro you have to DexCom

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the DexCom team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Dexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.

Founders & leadership

RD
Richard DoubledayExecutive
SRSteven R. Pacelli
Steven R. PacelliEVP & Managing Director, Dexcom Ventures2020–2025
JMJeffrey Moy
Jeffrey MoyExecutive
TH
Terrance H. GreggExecutive
JVJorge Valdes
Jorge ValdesChief Technology Officer2005–2017
JDJohn D. Lister
John D. ListerGeneral Manager, EMEA2015–2019
JRJess Roper
Jess RoperRetired CFO - Dexcom2005–2017Director at Revelation Biosciences
AK
Andrew K. BaloExecutive
JLJacob Leach
Jacob LeachPresident and Chief Executive Officer
JSJereme Sylvain
Jereme SylvainEVP, Chief Operating Officer
MBMichael Brown
Michael BrownExecutive Vice President, Chief Legal Officer
JCJon Coleman
Jon ColemanChief Commercial OfficerJon Coleman held executive leadership roles at Masimo, where he led global sales and operations and helped scale revenues to over $1 billion, as well as at Pfizer and Procter & Gamble in sales and international operations. He holds an MBA from Harvard Business School and a BA in International Relations from Brigham Young University.

Investors · 2

Reported raises · per SEC filings

Form D private placements

$7.2M disclosed across 1 round · 2016

▶$7.2MraisedMay 2016 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard DoubledayExecutive Officer
  • Eric TopolDirector
  • Barbara E. KahnDirector
  • Steven R. PacelliExecutive Officer
  • Jonathan T. LordDirector
  • Jeffrey MoyExecutive Officer
  • Nicholas AugustinosDirector
  • Terrance H. GreggExecutive Officer, Director
  • Jorge ValdesExecutive Officer
  • John D. ListerExecutive Officer
  • Jess RoperExecutive Officer
  • Andrew K. BaloExecutive Officer
  • Jay S. SkylerDirector
  • Kevin SayerExecutive Officer, Director
  • Steven R. AltmanDirector
  • Mark FolettaDirector
Offering amount
$7.2M
Amount sold
$7.2M
First sale
May 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Companies working in the same space as DexCom.

Frequently asked questions

What does DexCom do?
Dexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.
Who are DexCom's investors?
DexCom's investors include Canaan Partners, Black Diamond Ventures.
How much funding has DexCom raised?
DexCom has disclosed $7.2M raised across 1 round.
Where is DexCom headquartered?
DexCom is headquartered in San Diego, US.